Light Chain Bioscience
- Company typePrivate
- Founded1998
- HeadquartersPlan-les-ouates, Switzerland
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
Light Chain Bioscience firmographics
Firmographics- Name
- Light Chain Bioscience
- Legal name
- NovImmune SA
- Website
- https://lightchainbio.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Ownership category
- akta.pro rank
Light Chain Bioscience industry classification
Industry- Product category
- Bispecific Antibody Therapeutics (Oncology and Infectious Disease)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Light Chain Bioscience is headquartered
LocationHeadquarters
- HQ city
- Plan-les-ouates
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Light Chain Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Licensing Agreements - Upfront Payments: Edesa Biotech paid Series A-1 Convertible Preferred Shares at agreed value of $2.5 million upfront for TLR4 and CXCL10 antibody licenses. LegoChem/Iksuda partnership included $5 million upfront payment.
- Milestone Payments: Edesa Biotech provides up to $6.0 million near-term consideration plus up to $363.5 million in aggregate development, approval and commercial sales milestone payments. Takeda collaboration milestone for Factor VIII mimetic bispecific antibody discovery. LamKap Bio milestones for bispecific antibody designation as clinical candidates.
- Royalties on Sales: Light Chain Bioscience receives royalties based on commercial sales from licensed programs including Edesa Biotech agreement for COVID-19 treatments and Iksuda partnership for ADC LCB73.
- Sublicense Revenue: From LegoChem/Iksuda LCB73 ADC partnership, Light Chain receives prearranged percentage of sublicense revenue if Iksuda enters into license agreements with third party companies.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Light Chain Bioscience product offering
Product offeringCore offering
Light Chain Bioscience is a clinical-stage Swiss biotechnology company that develops multispecific antibody therapeutics built on its proprietary κλ body bispecific antibody platform, which produces fully native human IgG-format bispecific antibodies by combining a common heavy chain with kappa and lambda light chains. The company advances a pipeline of oncology and infectious-disease candidates internally and partners with pharmaceutical companies through exclusive licensing, co-development, and technology access agreements to take candidates into and through clinical development.
Product overview
Light Chain Bioscience is a clinical-stage biotechnology company developing a pipeline of bispecific antibody therapeutics built on its proprietary κλ body platform, which combines a common heavy chain with two different light chains (kappa and lambda) to create fully native human bispecific antibodies. The platform's lead programs include NI-1801 (CD47×mesothelin, in Phase II for ovarian cancer), NI-1701/TG-1801 (CD47×CD19, Phase I completed for B-cell malignancies), NILK-2301 (CEACAM5×CD3 T-cell engager, Phase I ongoing), NILK-2401 (CEACAM5×CD47, Phase I initiated), NI-3201 (PD-L1×CD28 costimulatory, entering clinic mid-2025), and earlier-stage programs including NI-2601/NI-2901 (CD47×PD-L1 dual checkpoint), NI-3501 (IL-2R/IL-15R tumor microenvironment activation), and FcRH5×CD28 (multiple myeloma). The company also has partnered programs including a Takeda hemophilia A Factor VIII mimetic and an Iksuda/LegoChem CD19 ADC. Three bispecific κλ bodies are currently in Phase I clinical evaluation.
Differentiator
Problem solved
Functional benefit
Products and services
- κλ Body Platform Proprietary bispecific antibody platform that combines a common heavy chain with two different light chains (one kappa and one lambda) and fully retains native human IgG structure; produced by simple co-expression of one heavy chain with two light chains and purified by affinity chromatography. Sold/licensed to pharma and biotech partners for multi-specific antibody development across oncology, infectious disease and other therapeutic areas.
- NI-1801 (CD47×mesothelin bispecific κλ body) CD47×mesothelin bispecific κλ body antibody designed to selectively block CD47 on mesothelin-expressing tumor cells and reverse tumor immune evasion while sparing healthy cells. Indicated for ovarian and mesothelin-positive solid tumors.
- NI-1701 / TG-1801 (CD47×CD19 bispecific κλ body) CD47×CD19 bispecific κλ body antibody that delivers selective CD47 blockade to CD19-positive B cells; co-developed with TG Therapeutics for relapsed/refractory B-cell lymphoma (DLBCL, FL, Burkitt lymphoma).
- NILK-2301 (CEACAM5×CD3 bispecific κλ body) CEACAM5×CD3 bispecific κλ body T-cell engager for CEA-positive solid tumors; Phase I clinical trial ongoing, developed in partnership with LamKap Bio Group.
- NILK-2401 (CEACAM5×CD47 bispecific κλ body) CEACAM5×CD47 bispecific κλ body antibody for immunotherapy of CEACAM5-expressing cancers; Phase I trial initiated with first patient dosed at START Madrid – FJD; developed with LamKap Bio Group.
- NI-2601 (CD47×PD-L1 bispecific antibody) Fc-active CD47×PD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors for dual immune checkpoint blockade; in late discovery/clinical lead stage.
- NI-2901 (CD47×PD-L1 bispecific antibody) CD47×PD-L1 bispecific antibody with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution for dual immune checkpoint blockade; in late discovery/clinical lead stage.
- NI-3201 (PD-L1×CD28 bispecific antibody) PD-L1×CD28 bispecific antibody designed to restore anti-tumor immunity by combining PD-L1 blockade with conditional PD-L1-dependent CD28 co-stimulation; demonstrated enhanced T-cell effector function, tumor regression, immunological memory and synergy with T-cell engagers in preclinical models.
- NI-3501 (IL-2R/IL-15R bispecific antibody pair) IL-2R/IL-15R bispecific antibody pair (IL-2Rβ×TAA and IL-2Rγ×TAA) for selective activation of IL-2/IL-15 signalling within the tumor microenvironment, minimizing systemic toxicities; in preclinical development for solid tumors.
- FcRH5×CD28 Bispecific Antibodies Bispecific antibodies targeting FcRH5 and CD28 designed to synergize with T-cell engagers for enhanced multiple myeloma treatment; presented at ASH 2024 (Poster #2796).
- Factor VIII Mimetic Bispecific Antibody (Takeda Program) Bispecific antibody with Factor VIII mimetic activity developed in partnership with Takeda Pharmaceutical Company Limited for the treatment of hemophilia A; discovery milestone achieved with the program advancing to IND-enabling studies.
- LCB73 (CD19-targeted ADC) CD19-targeted antibody-drug conjugate (ADC) candidate developed in partnership with LegoChem Biosciences and Iksuda Therapeutics for hematological tumors including DLBCL and Burkitt lymphoma; worldwide licensing agreement with $5M upfront and up to $222M in milestones.
Companies that use Light Chain Bioscience
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Light Chain Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Light Chain Bioscience partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered secondary and core.
- Universidad de Navarra & Hospital 12 de OctubresecondaryAdditional clinical trial sites for NILK-2401 Phase I study. Universidad de Navarra led by Prof Ignacio Melero and Dr. Mariano Ponz; Hospital 12 de Octubre led by Jon Zugazagoitia.
- Vall d'Hebron Institute of Oncology (VHIO)secondaryClinical trial site for NILK-2301 Phase I study for CEACAM5xCD3 bispecific antibody. Led by Prof Josep Tabernero. Partner in collaboration with LamKap Bio for clinical development of CEACAM5-targeting programs.
- START Madrid - FJDsecondaryClinical trial site for NILK-2401 Phase I study in CEACAM5-expressing solid cancers. Led by Dr. Victor Moreno. One of four clinical sites including VHIO, Universidad de Navarra, and Hospital 12 de Octubre.
- Lonza Pharma & BiotechsecondaryContract manufacturing partner for GMP production of κλ body bispecific antibodies. Successfully manufactured therapeutic candidates at 1000-liter scale with high yields. Used for GMP manufacturing with LamKap Bio's partner for clinical development candidates.
- TG TherapeuticscoreGlobal collaboration for TG-1801 (NI-1701) bispecific antibody targeting CD19 and CD47 for B-cell malignancies. Phase I clinical trial conducted in Australia with subsequent IND approval and Phase I initiation in US. Company announced predefined milestone achievement in May 2021.
- Discoveric bio groupsecondaryTwo research collaborations: (1) Multi-specific antibodies against bacterial antigens for multidrug-resistance treatment, and (2) Brain-penetrating multi-specific antibodies for neurodegenerative disorders including Alzheimer's disease. Light Chain receives upfront, milestones, and tiered royalties on net sales.
- LamKap Bio GroupcoreResearch collaboration for T cell retargeting bispecific antibodies blocking CD47 for solid cancer treatment. Two milestones achieved for designation of clinical candidates advancing to IND-enabling studies and GMP manufacturing with Lonza. LamKap Bio leads clinical development for NILK-2301 (CEACAM5xCD3) and NILK-2401 (CEACAM5xCD47) programs.
- LegoChem Biosciences & Iksuda TherapeuticscoreWorldwide license agreement for LCB73 CD19-targeted ADC for hematological tumors. Iksuda made $5M upfront payment with up to $222M in milestones. Light Chain Bioscience shares in all payments as antibody provider. ADC combines LCB's linker/toxin platform with Light Chain's CD19 antibody.
- Edesa BiotechcoreExclusive worldwide license for development and commercialization of anti-TLR4 and anti-CXCL10 monoclonal antibodies for acute respiratory distress syndrome and COVID-19. Edesa paid $2.5M upfront and up to $363.5M in milestones plus royalties. Positive Phase 2 data announced with 68.5% mortality reduction in hospitalized COVID-19 patients.
- Takeda Pharmaceutical CompanysecondaryCollaboration for Factor VIII mimetic bispecific antibodies for hemophilia A treatment. Milestone achieved for successful completion of discovery phase and designation of undisclosed bispecific antibodies as clinical development candidates advancing to IND-enabling studies.
Scale indicators4 records
Recent moves7 records
Light Chain Bioscience competitors and assessment
Company assessmentDirect peers
- MacroGenics: MacroGenics develops bispecific antibodies using its DART platform, with oncology-focused programs targeting immune checkpoints and tumor antigens (e.g., MGC018, vobramitamab duocarmazine). Direct peer in bispecific antibody technology development with similar partnership-based business model and pipeline focus on immuno-oncology.
- Harpoon Therapeutics: Harpoon Therapeutics develops T-cell engagers using its proprietary TriTAC platform, including HPN328 (DLL3-targeted) and HPN217 (BCMA-targeted). Direct competitor in immuno-oncology with bispecific/T-cell engager technology, targeting similar hematological and solid tumor indications.
- Genmab: Genmab is a leading bispecific antibody technology company with its proprietary DuoBody platform, developing multiple oncology bispecifics including epcoritamab. Direct competitor in the bispecific antibody platform space serving similar pharma partners with similar technology licensing and co-development models.
- ALX Oncology: ALX Oncology develops CD47-blocking therapeutics (evorpacept/ALX148) for solid tumors and hematologic malignancies. Direct peer in the CD47-targeting space, pursuing similar approaches to enable selective tumor cell killing while sparing healthy cells, comparable in pipeline stage and partnership-driven model.
- Zymeworks: Zymeworks develops bispecific and multifunctional therapeutics using its Azymetric platform, with a pipeline including zanidatamab (HER2-targeted bispecific). Direct competitor in bispecific antibody platform technology with similar licensing/co-development business model targeting oncology.
- Trillium Therapeutics: Trillium (acquired by Pfizer in 2021) developed CD47-targeting therapeutics (TTI-621, TTI-622) for hematological malignancies and solid tumors, directly competing with Light Chain's CD47×CD19 (NI-1701) and CD47×mesothelin (NI-1801) programs in the immuno-oncology space.
Emerging players
- Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing oncology therapeutics including bispecific antibodies and immune modulators (e.g., CLN-978 targeting CD19). Comparable emerging-stage company with a similar focused approach to immuno-oncology and bispecific antibody development.
- Adagene: Adagene is a clinical-stage biotech developing antibody therapeutics using its NEObody, POWERbody, and ADCC enhanced antibody platforms. Emerging competitor in antibody engineering with similar bispecific and immune-engaging therapeutic candidates targeting oncology.
- CytomX Therapeutics: CytomX develops Probody therapeutics - masked antibodies that are activated in the tumor microenvironment, with bispecific candidates in its pipeline. Comparable biotech using protein engineering approaches to achieve tumor-selective antibody activity, similar to Light Chain's approach of restricting CD47 blockade to tumor cells.
Broad incumbents
- Roche: Roche is the incumbent leader in bispecific antibodies with Hemlibra (emicizumab), a Factor VIII mimetic bispecific antibody for hemophilia A that competes with Light Chain's Takeda-partnered Factor VIII mimetic program. Broad pharma with multiple internal bispecific platforms and a commercial bispecific already on the market, representing both a competitive threat and a potential acquirer.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Light Chain Bioscience social profiles
Digital presenceLight Chain Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Light Chain Bioscience leadership team
Management profileNumber of profiles
Profiles8 records
Light Chain Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Light Chain Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Light Chain Bioscience
What does Light Chain Bioscience do?
Light Chain Bioscience is a clinical-stage Swiss biotechnology company that develops multispecific antibody therapeutics built on its proprietary κλ body bispecific antibody platform, which produces fully native human IgG-format bispecific antibodies by combining a common heavy chain with kappa and lambda light chains. The company advances a pipeline of oncology and infectious-disease candidates internally and partners with pharmaceutical companies through exclusive licensing, co-development, and technology access agreements to take candidates into and through clinical development.
Is Light Chain Bioscience a public or private company?
Light Chain Bioscience is a private company. It is classified as unknown and is currently operating.
When was Light Chain Bioscience founded?
Light Chain Bioscience was founded in 1998.
Where is Light Chain Bioscience based?
Light Chain Bioscience is headquartered in Plan-les-ouates, Switzerland, in the Europe region.
How does Light Chain Bioscience make money?
Four revenue lines are on record. Licensing Agreements - Upfront Payments are the primary driver. The others are milestone Payments, royalties on Sales and sublicense Revenue.
Who are Light Chain Bioscience's main competitors?
Direct peers on record are MacroGenics, Harpoon Therapeutics, Genmab, ALX Oncology, Zymeworks and Trillium Therapeutics. Emerging players are Cullinan Oncology, Adagene and CytomX Therapeutics. Roche is listed as a broad incumbent.
Does Light Chain Bioscience have an API?
No public API is recorded for Light Chain Bioscience.
What industry is Light Chain Bioscience in?
Light Chain Bioscience's product category is Bispecific Antibody Therapeutics (Oncology and Infectious Disease). Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.